NeoGenomics, Inc. specializes in providing cancer-focused diagnostic and testing services through an extensive network of laboratories located across the United States, Europe, and Asia. The company operates through two distinct divisions: Clinical Services and Pharma Services. Its comprehensive offerings cater to a diverse clientele, including hospitals, reference laboratories, pathologists, oncologists, clinicians, pharmaceutical companies, and researchers. NeoGenomics' advanced testing capabilities encompass cytogenetics, which examines normal and abnormal chromosomes in relation to disease; fluorescence in-situ hybridization (FISH) for detecting and pinpointing specific DNA sequences and genes on chromosomes; and flow cytometry, used to measure cell population characteristics. Additionally, the company provides immunohistochemistry and digital imaging services, enabling the localization of cellular proteins in tissue sections, visualization of scanned slides, and quantitative analysis. Molecular testing, focusing on DNA/RNA analysis and gene structure/function, is also a key offering, alongside morphologic analysis where pathologists microscopically diagnose cells. Beyond clinical diagnostics, NeoGenomics supports pharmaceutical clients' oncology programs from discovery to commercialization and acts as a reference laboratory for anatomic pathology testing. The company, founded in 2001 and headquartered in Fort Myers, Florida, also maintains a strategic alliance and laboratory services agreement with Inivata Limited.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $660.57M | $591.64M | $509.73M | $484.33M | $444.45M | $408.83M | $276.74M | $240.25M |
| Cost of Revenue | $370.47M | $347.04M | $321.83M | $297.27M | $258.56M | $211.99M | $149.48M | $138.29M |
| Gross Profit | $290.10M | $244.60M | $187.90M | $187.06M | $185.89M | $196.84M | $127.27M | $101.96M |
| Gross Margin | 43.92% | 41.34% | 36.86% | 38.62% | 41.83% | 48.15% | 45.99% | 42.44% |
| Operating Expenses | $382.21M | $352.34M | $345.52M | $305.81M | $199.88M | $183.83M | $117.22M | $99.05M |
| Operating Income | $-92.11M | $-107.74M | $-157.62M | $-118.75M | $-13.99M | $13.01M | $10.04M | $2.90M |
| Operating Margin | -13.94% | -18.21% | -30.92% | -24.52% | -3.15% | 3.18% | 3.63% | 1.21% |
| Net Income | $-78.73M | $-87.97M | $-144.25M | $-8.35M | $4.17M | $8.01M | $2.64M | $-396.00K |
| Net Margin | -11.92% | -14.87% | -28.30% | -1.72% | 0.94% | 1.96% | 0.95% | -0.16% |
| EPS (Basic) | $-3.10 | $-3.50 | $-5.80 | $-0.35 | $0.19 | $0.40 | $0.14 | $-0.03 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |